Revolution Medicines (RVMD) Research & Development (2019 - 2026)
Revolution Medicines (RVMD) posted Research & Development of $394.9 million for Q2 2026, up 14.81% on a QoQ basis from $344.0 million in Q1 2026, and up 76.2% year-over-year from $224.1 million in Q2 2025.
Powered by 
Analysis
Revolution Medicines (RVMD) Research & Development (2019 - 2026) Analysis & Trends
Revolution Medicines has reported Research & Development for 8 years, with the latest figure at $394.9 million in Q2 2026.
- On a quarterly basis, Research & Development rose 76.2% year-over-year to $394.9 million in Q2 2026; TTM through Jun 2026 was $1.3 billion, a 68.41% increase from a year earlier, with the FY2025 full-year figure at $987.3 million, up 66.72% from the prior year.
- Research & Development was $394.9 million for Q2 2026 at Revolution Medicines, up from $344.0 million in the prior quarter.
- The five-year high for Research & Development was $394.9 million in Q2 2026, with the low at $56.5 million in Q1 2022.
- Average Research & Development over 5 years is $166.4 million, with a median of $141.7 million recorded in 2023.
- The largest YoY upside for Research & Development was 124.54% in 2023 against a maximum downside of 22.05% in 2023.
- Over 5 years, Research & Development stood at $66.1 million in 2022, then surged by 124.54% to $148.5 million in 2023, then climbed by 26.68% to $188.1 million in 2024, then jumped by 56.8% to $294.9 million in 2025, then jumped by 33.9% to $394.9 million in 2026.
- The last three Research & Development figures came in at $394.9 million (Q2 2026), $344.0 million (Q1 2026), and $294.9 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 649.01 Bn | 628.25 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 468.55 Bn | 462.03 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 365.49 Bn | 358.40 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 272.39 Bn | 265.10 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Astrazeneca | 253.18 Bn | 247.96 Bn | 12.86 Bn | -4.05 Bn |
| 6 | Amgen | 219.53 Bn | 205.54 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 187.85 Bn | 184.59 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 160.56 Bn | 149.16 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Vertex Pharmaceuticals | 130.81 Bn | 122.96 Bn | 2.84 Bn | 993.80 Mn |
| 10 | Revolution Medicines | 40.86 Bn | 40.86 Bn | - | 394.92 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 394.92 Mn |
| Mar 31, 2026 | 343.97 Mn |
| Dec 31, 2025 | 294.94 Mn |
| Sep 30, 2025 | 262.51 Mn |
| Jun 30, 2025 | 224.13 Mn |
| Mar 31, 2025 | 205.75 Mn |
| Dec 31, 2024 | 188.10 Mn |
| Sep 30, 2024 | 151.75 Mn |
| Jun 30, 2024 | 134.93 Mn |
| Mar 31, 2024 | 118.02 Mn |
| Dec 31, 2023 | 148.48 Mn |
| Sep 30, 2023 | 107.74 Mn |
| Jun 30, 2023 | 97.98 Mn |
| Mar 31, 2023 | 68.95 Mn |
| Dec 31, 2022 | 66.13 Mn |
| Sep 30, 2022 | 69.46 Mn |
| Jun 30, 2022 | 61.00 Mn |
| Mar 31, 2022 | 56.49 Mn |
| Dec 31, 2021 | 53.68 Mn |
| Sep 30, 2021 | 46.47 Mn |
API Access
Revolution Medicines Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=RVMD&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "RVMD", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=RVMD&period=max&api_key=YOUR_API_KEY");
const data = await res.json();